Rigel Pharmaceuticals (RIGL) FCF Margin (2010 - 2026)
Rigel Pharmaceuticals (RIGL) recorded quarterly FCF Margin of 4.63% in Q1 2026, down 85.3% quarter-over-quarter from 31.51% in Q4 2025, and up 631.0% on a YoY basis from 0.63% in Q1 2025.
Rigel Pharmaceuticals (RIGL) FCF Margin (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' FCF Margin history runs 16 years deep, the most recent figure standing at 4.63% for Q1 2026.
- In Q1 2026, FCF Margin rose 631.0% year-over-year to 4.63%; the TTM figure through Mar 2026 stood at 26.45% (up 894.0% YoY), while the FY2025 annual figure was 25.71%, up 817.0% from the prior year.
- FCF Margin was 4.63% for Q1 2026 at Rigel Pharmaceuticals, down from 31.51% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 39.2% in Q3 2024 to a low of 154.53% in Q1 2022.
- Historically, FCF Margin has averaged 9.96% across 5 years, with a median of 1.67% in 2025.
- The sharpest annual moves came in 2022 and 2023: FCF Margin slumped 25185 bps in 2022, then soared 13891 bps in 2023.
- A 5-year view of FCF Margin shows it stood at 42.87% in 2022, then jumped by 59 bps to 17.43% in 2023, then surged by 244 bps to 25.14% in 2024, then gained by 25 bps to 31.51% in 2025, then slumped by 85 bps to 4.63% in 2026.
- The last three FCF Margin figures came in at 4.63% (Q1 2026), 31.51% (Q4 2025), and 34.6% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Rigel Pharmaceuticals | 603.18 Mn | 456.49 Mn | 54.21 Mn | 4.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.63% |
| Dec 31, 2025 | 31.51% |
| Sep 30, 2025 | 34.60% |
| Jun 30, 2025 | 30.03% |
| Mar 31, 2025 | -1.67% |
| Dec 31, 2024 | 25.14% |
| Sep 30, 2024 | 39.20% |
| Jun 30, 2024 | 0.82% |
| Mar 31, 2024 | -16.97% |
| Dec 31, 2023 | -17.43% |
| Sep 30, 2023 | -4.83% |
| Jun 30, 2023 | 22.06% |
| Mar 31, 2023 | -15.63% |
| Dec 31, 2022 | -42.87% |
| Sep 30, 2022 | -60.20% |
| Jun 30, 2022 | -43.18% |
| Mar 31, 2022 | -154.53% |
| Dec 31, 2021 | -93.41% |
| Sep 30, 2021 | -48.59% |
| Jun 30, 2021 | 208.67% |